BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

It was designed to be the oral fix for hereditary angioedema (HAE) — a rare, potentially life-threatening genetic disorder — but BioCryst Pharmaceutical’s experimental capsule has underwhelmed in a pivotal late-stage study, despite meeting the primary endpoint.